Top Ten most popular articles on Pharmafile.com this week
pharmafile | January 27, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
We’re nearing the end of the first month of the year and acqusitions have begun to introduce themselves with bang, with big money being paid for certain companies. Nevertheless, it didn’t stop the most read news of the week being the questionable activity of one company.
Roche’s drug, Actemra (also known as RoActemra in Europe), has been granted priority review designation by the FDA for the treatment of giant cell arteritis (GCA).
The PhRMA has announced the launch of a new multi-million dollar advertising and public relations campaign in response to criticisms including recent comments form president Trump.
Research into statins has revealed a surprising potential use in cancer treatment, with the drug potentially preventing the spread and growth of cancer cells.
Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be pursuing an accelerated regulatory pathway for Opdivo with Yervoy, and it revealed some with the news that it had reached a patent infringement settlement with MSD.
Mallinckrodt Pharmaceuticals has hit the headlines for particularly dispiriting reasons – with further evidence of practise by some companies that plumbs new depths for the pharmaceutical industry.
The potential solutions offered by ‘big data’ seems to offer a vision of the future but potential solutions aren’t enough for those in need of medication now. This feature takes a look at what big data can offer the pharmaceutical industry and patients at present.
Pancreatic cancer is notoriously difficult to treat, having the lowest survival rates of all cancers in Britain. The research displaying combination treatments improving survival rates is incredibly promising, even more so that both drugs are off-patent and therefore affordable.
Johnson & Johnson have successfully agreed a deal to acquire Actelion. The deal has been murmuring in the background of the pharmaceutical industry for months before today’s announcement.
Pharmafile’s look ahead to the trends to expect this year continues to remain a presence in our Top 10 stories.
Hetero Labs, an Indian pharmaceutical firm, has been observed by the FDA shredding what the FDA judged to be controlled documents, with suggestions that they were batch packaging records and batch manufacturing records.
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer …